In the latest quarter, 14 analysts provided ratings for Arcellx ACLX, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 11 | 3 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 9 | 3 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Arcellx and provided 12-month price targets. The average target is $107.71, accompanied by a high estimate of $136.00 and a low estimate of $95.00. Observing a 21.9% increase, the current average has risen from the previous average price target of $88.36.
Interpreting Analyst Ratings: A Closer Look
The standing of Arcellx among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Gil Blum | Needham | Maintains | Buy | $105.00 | $105.00 |
| Asthika Goonewardene | Truist Securities | Raises | Buy | $136.00 | $87.00 |
| Emily Bodnar | HC Wainwright & Co. | Raises | Buy | $115.00 | $95.00 |
| Biren Amin | Piper Sandler | Raises | Overweight | $115.00 | $91.00 |
| Gil Blum | Needham | Raises | Buy | $105.00 | $96.00 |
| Judah Frommer | Morgan Stanley | Raises | Overweight | $106.00 | $81.00 |
| Jason Gerberry | B of A Securities | Raises | Buy | $100.00 | $84.00 |
| Jack Allen | Baird | Raises | Outperform | $106.00 | $77.00 |
| Emily Bodnar | HC Wainwright & Co. | Raises | Buy | $95.00 | $80.00 |
| Gil Blum | Needham | Maintains | Buy | $96.00 | $96.00 |
| Gil Blum | Needham | Maintains | Buy | $96.00 | $96.00 |
| Gil Blum | Needham | Raises | Buy | $96.00 | $81.00 |
| Benjamin Burnett | Stifel | Raises | Buy | $122.00 | $83.00 |
| John Newman | Canaccord Genuity | Raises | Buy | $115.00 | $85.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Arcellx. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Arcellx compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Arcellx's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
For valuable insights into Arcellx's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Arcellx analyst ratings.
Delving into Arcellx's Background
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
Arcellx: A Financial Overview
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Arcellx's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 74.03%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -99.37%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -5.33%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Arcellx's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.45%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Arcellx's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.14.
The Significance of Analyst Ratings Explained
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
